Par Drugs and Chemicals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Par Drugs and Chemicals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 17.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings Working Against Par Drugs and Chemicals Limited's (NSE:PAR) Share Price Following 26% Dive
Dec 20
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise
Oct 29Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified
Apr 16Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Apr 05Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?
Nov 03If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity
May 19Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?
Mar 17Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?
Oct 22Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings
Aug 11Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching
Jul 14Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?
Mar 31Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?
Mar 05Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)
Feb 06
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Jan 10How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?
Dec 13In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Par Drugs and Chemicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 1,041 | 183 | 145 | 172 | N/A |
| 6/30/2024 | 953 | 146 | N/A | N/A | N/A |
| 3/31/2024 | 956 | 145 | 142 | 202 | N/A |
| 12/31/2023 | 973 | 142 | N/A | N/A | N/A |
| 9/30/2023 | 962 | 127 | 140 | 227 | N/A |
| 6/30/2023 | 952 | 115 | N/A | N/A | N/A |
| 3/31/2023 | 957 | 113 | 57 | 134 | N/A |
| 12/31/2022 | 933 | 103 | N/A | N/A | N/A |
| 9/30/2022 | 873 | 106 | 32 | 76 | N/A |
| 6/30/2022 | 821 | 91 | N/A | N/A | N/A |
| 3/31/2022 | 751 | 92 | 44 | 76 | N/A |
| 12/31/2021 | 692 | 112 | N/A | N/A | N/A |
| 9/30/2021 | 686 | 112 | 4 | 67 | N/A |
| 6/30/2021 | 631 | 115 | N/A | N/A | N/A |
| 3/31/2021 | 608 | 116 | 70 | 121 | N/A |
| 12/31/2020 | 579 | 88 | N/A | N/A | N/A |
| 9/30/2020 | 550 | 83 | 102 | 120 | N/A |
| 6/30/2020 | 554 | 65 | 82 | 98 | N/A |
| 3/31/2020 | 558 | 48 | 61 | 77 | N/A |
| 12/31/2019 | 532 | 41 | N/A | N/A | N/A |
| 9/30/2019 | 506 | 20 | 12 | 17 | N/A |
| 6/30/2019 | 484 | 23 | 15 | 19 | N/A |
| 3/31/2019 | 463 | 25 | 30 | 34 | N/A |
| 3/31/2018 | 424 | 15 | N/A | 46 | N/A |
| 3/31/2017 | 488 | 18 | N/A | 92 | N/A |
| 3/31/2016 | 333 | 4 | N/A | 65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PAR's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if PAR's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if PAR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if PAR's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if PAR's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PAR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:43 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Par Drugs and Chemicals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|